Complete title: A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (Mi-Immune)
| Research Study Number | RG1005060 |
| Principal Investigator | Masumi Ueda Oshima |
| Phase | III |
1801: The goal of this protocol is to test the primary hypothesis that the engraftment stool microbiome diversity predicts one-year non-relapse mortality in patients undergoing reduced intensity allogeneic HCT.
Other eligibility criteria may apply.
| Research Study Number | RG1005060 |
| Contact | Seattle Cancer Care Alliance Intake Office |
| Telephone | 800-804-8824 / 206-606-1024 |
Keywords: Lymphoma; Myelodysplastic Syndromes (MDS); Bone Marrow Diseases; Leukemia, Chronic Myelogenous
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.